Rapiscan (Regadenoson)

Rapiscan is the only approved hyperaemic stress agent for myocardial perfusion imaging (MPI) and fractional flow reserve (FFR)1

Rapiscan is a pharmacological stress agent used to simulate the effect of exercise (for those who are unable to exercise). It is used in the diagnosis of coronary artery disease, ensuring subsequent treatment is optimised.1

Rapiscan was developed specifically to address the needs of nuclear medicine and interventional cardiology by simplifying the pharmacological stress protocol, improving patient tolerability and providing an option for patients with asthma and COPD.1

References

1.GE Healthcare. Rapiscan Summary of Product Characteristics, 2019.

Rapiscan is the only approved hyperaemic stress agent for myocardial perfusion imaging (MPI) and fractional flow reserve (FFR)1

Rapiscan is a pharmacological stress agent used to simulate the effect of exercise (for those who are unable to exercise). It is used in the diagnosis of coronary artery disease, ensuring subsequent treatment is optimised.1

Rapiscan was developed specifically to address the needs of nuclear medicine and interventional cardiology by simplifying the pharmacological stress protocol, improving patient tolerability and providing an option for patients with asthma and COPD.1

References

1.GE Healthcare. Rapiscan Summary of Product Characteristics, 2019.

Fast Facts

1. European Heart Network. European Cardiovascular Disease Statistics 2017. Available at: www.ehnheart.org/cvd-statistics.html (accessed August 2019).
2. GE Healthcare. Rapiscan Summary of Product Characteristics, 2019.
3. Azzouz MS et al. J Am Coll Cardiol 2015; 66(15); B118–B119.


Coronary artery disease is a global health problem
CAD is a global health problem with a prevalence of ~330 million in 2017–2018, and is the leading cause of death worldwide (1)
Management of CAD
Management of CAD includes lifestyle changes, medical therapies, medical procedures and surgery, in addition to cardiac rehabilitation. (1-3)
Myocardial perfusion imaging
SPECT MPI performed during stress and at rest is an established method for diagnosing CAD, assessing risk of future cardiac events and informing treatment decisions. (1)
Fractional flow reserve
FFR is helpful as an adjunct to coronary angiography in guiding therapeutic decision making in CAD and FFR-guided revascularization, and is the gold standard for evaluating stenotic significance (Figure 1). (1)
Mode of Action
Rapiscan® (regadenoson) is the first and only selective A2A adenosine receptor agonist licensed for cardiac functional imaging. (1)
Clinical efficacy
Rapiscan is indicated for myocardial perfusion imaging (MPI) and Fractional Flow Reserve (FFR) examinations with results comparable with adonesine. (1)
Easy to administer
Rapiscan is delivered into a single, fixed dose with no need for infusion pump and weight-based dosing adjustment. (1)
Improved tolerability over adenosine
Well tolerated, with adverse events mostly mild and transient. (1) Several studies suggest that Rapiscan has a favorable side-effect profile in comparison with adenosine. (1,2)
Administration in asthmatic and COPD patients
Rapiscan can be used in patients with pulmonary conditions, based on data derived from MPI clinical settings. (1)
Case studies demonstrating the use of Rapiscan in the measurement of FFR
Rapiscan is a selective A2A receptor agonist approved for the measurement of FFR. (1) The following two case studies illustrate the efficacy and tolerability of Rapiscan in the measurement of FFR when evaluating the functional significance of stenosis in patients with suspected CAD.
Case study 1
FFR using Rapiscan in a 44-year-old female patient with stenosis and angina on moderate exertion Case study courtesy of Professor Nico Pijls
Case study 2
FFR using Rapiscan in a 70-year-old male patient with stenosis in the LAD Case study courtesy of Professor Nico Pijls

Rapportera biverkningar

Prescribing Information